DrugBiological
Dazodalibep clinical trials
Also written VIB4920 and MEDI4920.
- studies test it
- 11
- open now
- 2
- in phase 3
- 3
- first study started
- 2014
Keep track of what changes. Save the dazodalibep studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
11 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2019 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
Amgen (8) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · MedImmune LLC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dazodalibep is read from its arms, and is right about nine times in ten.
Testing it · 11
- VIBRANT: VIB4920 for Active Lupus NephritisRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05201469Written as VIB4920
- A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)RecruitingPhase 3AmgenNCT06747949Written as Dazodalibep
- A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityCompletedPhase 3AmgenNCT06104124Written as Dazodalibep
- CD40L Antagonism in Rheumatoid Arthritis (RA)TerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05306353Written as VIB4920 without TNFi
- A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateActive, not recruitingPhase 3AmgenNCT06245408Written as Dazodalibep
- A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's SyndromeCompletedPhase 2AmgenNCT04129164Written as VIB4920
- A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney TransplantCompletedPhase 2AmgenNCT04046549Written as VIB4920
- A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid ArthritisCompletedPhase 1AmgenNCT02780388Written as VIB4920
- A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid ArthritisCompletedPhase 2AmgenNCT04163991Written as VIB4920
- Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorWithdrawnPhase 2AmgenNCT04174677Written as VIB4920
- Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy AdultsCompletedPhase 1MedImmune LLCNCT02151110Written as MEDI4920 3 mg
Codes
What other systems call dazodalibep · ClinicalTrials.gg INT016787
- UNII (FDA) HN5US76BWFDAZODALIBEPOne source FDA
- NCI Thesaurus C175714DazodalibepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HN5US76BWF | DAZODALIBEP | One source FDA |
| NCI Thesaurus | C175714 | Dazodalibep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.